Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665Burton Eisenberg, Margaret von Mehren, Jonathan Harris et al.|Journal of Surgical Oncology|2008Cited by 419
Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132Dian Wang, Burton Eisenberg, Michael C. Heinrich et al.|Annals of Surgical Oncology|2011Cited by 202
Soft Tissue SarcomaGeorge D. Demetri, Jeffrey D. Wayne, Scott Antonia et al.|Journal of the National Comprehensive Cancer Network|2010Cited by 167
Soft Tissue Sarcoma, Version 2.2014Margaret von Mehren, Hema Sundar, R. Lor Randall et al.|Journal of the National Comprehensive Cancer Network|2014Cited by 150
Soft Tissue Sarcoma, Version 2.2012Margaret von Mehren, Nicole R. McMillian, Robert S. Benjamin et al.|Journal of the National Comprehensive Cancer Network|2012Cited by 149